We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
-23.1%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$171M
AUM Growth
-$49.1M
(-22%)
Cap. Flow
+$32.3M
Cap. Flow % of AUM
Cap. Flow %
18.88%
Top 10 Holdings %
Top 10 Hldgs %
94.62%
Holding
20
New
4
Increased
–
Reduced
1
Closed
3
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHMA
Chiasma
CHMA
|
+$51.7M |
| 2 |
Cymabay Therapeutics
CBAY
|
+$4.36M |
| 3 |
Dermira
DERM
|
+$1.7M |
| 4 |
EPRS
Epirus Biopharmaceuticals
EPRS
|
+$46.4K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amarin
AMRN
|
+$19.8M |
| 2 |
ZGNX
Zogenix
ZGNX
|
+$3.92M |
| 3 |
CEMP
Cempra
CEMP
|
+$1.67M |
| 4 |
ZLCS
Zalicus
ZLCS
|
+$45K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Miscellaneous | 0.02% |
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q3 2015 Portfolio in Review
As of Q3 2015, Abingworth held 20 positions worth $171M, down 22% from $220M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Abingworth deployed $32.3M of net new capital in Q3 2015, opening 4 new positions. Its largest new stake was Chiasma: 2,080,595 shares worth $41.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Cempra, an estimated $1.67M trimmed.
- Abingworth's largest Q3 2015 buy was Chiasma: 2,080,595 shares worth $41.4M.
- Abingworth's biggest Q3 2015 reduction was Cempra, cutting an estimated $1.67M.
- Abingworth fully exited Amarin in Q3 2015, selling an estimated $19.8M.
- Abingworth's ten largest holdings make up 95% of its $171M portfolio in Q3 2015.
- Abingworth opened 4 new positions and closed 3 in Q3 2015.
- Abingworth's portfolio value fell 22% quarter-over-quarter to $171M.
Based on Abingworth's 13F filing for Q3 2015, filed 13 Nov 2015.